# A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct06079346/  
OnCo record `nct06079346` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing Trabedersen in pancreatic ductal adenocarcinoma, now recruiting.

## Summary

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer is a phase 2/3 interventional study registered as NCT06079346, led by Oncotelic, and recruiting on the registry. Official title: A Randomised Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer. Planned enrolment is 455 participants (estimated). The study started in 2024-05-01 and primary completion is expected in 2026-06-01. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: STOP-PC
- Tags: ctgov-ingest
- Registry id: NCT06079346
- Phase: 2/3
- Setting: A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
- Sponsor: Oncotelic
- Enrolled: 455

## Sources

- ClinicalTrials.gov NCT06079346: https://clinicaltrials.gov/study/NCT06079346

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Trabedersen](https://onco.cc/drugs/trabedersen/)

---
JSON: https://onco.cc/api/v1/entities/nct06079346.json